Natural product-derived therapy for Human Leukemias: Ganoderma lucidum suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 10/December/2014, 11.48 pm

Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: MyoD increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 10/December/2016, 11.18 pm
December 10, 2016
Natural product-derived therapy for Human Leukemias: Eriocitrin, found in lemons, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 10/December/2016, 11.56 pm
December 10, 2016
Show all

Introduction: What they say:

Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.” 


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-derived therapy for Human Leukemias: Ganoderma lucidum suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4. 


From Research findings to Therapeutic opportunity:

This study suggests that Ganoderma lucidum extract, by increasing the expression of  its target gene, it may increase the expression of a number of tumor suppressor genes, including IRF4. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias (fig. 1).

ganoderma_lucidum

Figure1. Ganoderma lucidum. Ganoderma lucidum extract increases the expression IRF4 and inhibits the progression of B-Cell and myeloid leukemias via up regulation of its target gene

Taken together, this study suggests that pharmacological formulations encompassing Ganoderma lucidum extract or an active compound isolated from it may be used to inhibit B-Cell and myeloid leukemias.

# Research cooperation


Details of the research details

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Ganoderma lucidum increases the expression of IRF4?

Amount: $ 50

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or newbioideas.com

CitationBoominathan, L., Natural product-derived therapy for Human Leukemias: Ganoderma lucidum suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 10/December/2016, 11.48 pm,  Genome-2-Bio-Medicine Discovery Center.

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.